Skip to main content
OpenTrials
Completed

NCT Number: NCT02143037

CM Treatment for Alcohol Dependence Using New Technology

Contingency management (CM) is highly efficacious for reducing substance use, and recent data suggest that reinforcing attendance at treatment can significantly improve treatment outcomes. Importantly, CM interventions that reinforce attendance are more likely to be adopted clinically than those that reinforce abstinence. Having objective indicators of drinking outcomes, nevertheless, is critical for quantifying the benefits of attendance-based CM treatment in alcohol abusing populations. New technology is now available to gauge alcohol use in patients' natural environments. The Secure Continuous Remote Alcohol Monitor (SCRAMx®) continuously monitors alcohol consumption 24 hours a day. As such, it may be ideal for objective evaluation of alcohol consumption during treatment intervention studies, including those that involve CM.

In this study, 114 patients participating in community based outpatient treatment programs for alcohol use disorders will wear SCRAMx for a 12-week period. They will be randomized to standard care or standard care plus CM, with reinforcement contingent upon attendance at treatment. The investigators will assess treatment attendance and alcohol use via SCRAMx and self reports. The investigators expect that patients randomized to the CM intervention will remain in treatment longer and show reductions in both SCRAMx assessed and self reported drinking days relative to those randomized to standard care.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Regional Network of Programs, Inc., Bridgeport, Connecticut, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • age 18 years or older
  • current diagnosis of alcohol use disorder
  • able to pass an informed consent quiz
  • agree to wear a SCRAMx monitor for 12 weeks
  • have a standard, SCRAMx compatible phone line in their home or agree to attend the clinic at least every other week for data downloads
  • agree to sign an off-campus property transfer form and return SCRAMx equipment in 12 weeks

Exclusion criteria

  • serious, uncontrolled psychiatric illness
  • in recovery from pathological gambling
  • unstable address
  • intend to participate in activities incompatible with SCRAMx in the next 3 months
  • are wearing SCRAMx for legal purposes

Treatment and study plan

prize contingency management for attending treatment

Behavioral

Usual Care

Behavioral

Primary outcomes

  1. longest duration of actively attending treatment

    Time frame: 3 months

    patient attendance to treatment groups as verified by clinic records (number of days attended out of number of days expected to treatment)

Sponsors and collaborators

Lead sponsor

UConn Health

Other

Collaborators

  • National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Registry information

Important dates

Study start
2013
Primary completion
2018
Study completion
2018
First posted
May 20, 2014
Registry last updated
May 17, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.